- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
We're proud to add this remarkable analyst to our team of writers.
Check out his first piece on the red-hot Baltic Dry Index.
In the presence of His Greatness, Warren Buffett, media coverage of Berkshire Hathaway's annual meeting delivered Old Testament-style reverence and not much else.
RealMoney's experts were full of insight about Berkshire Hathaway and Sepracor
The longtime CNBC anchor joins our star-studded team today.
One of our pros made calls that could have kept you out two ETFs that have been decimated.
Let our RealMoney experts help you make money. Look at some of these profitable calls.
Adam Feuerstein's Biotech Select portfolio has had some big wins lately.
The board of General Motors back in 1992 did what few boards do -- it took decisive action to shake up management and fix the company.